Park­er In­sti­tute backs an up­start biotech look­ing to de­vel­op a new, con­vert­ible CAR-T

The bil­lion­aire-backed Park­er In­sti­tute for Can­cer Im­munother­a­py is in­vest­ing and part­ner­ing with a biotech their re­searchers be­lieve has the po­ten­tial to de­vel­op a new-mod­el CAR-T that can be bet­ter guid­ed down nar­row path­ways and equipped with a con­ve­nient on/off switch to help avoid any fa­tal ac­ci­dents.

Jef­frey Blue­stone

Park­er CEO Jef­frey Blue­stone isn’t giv­ing away any num­bers right now, but he says the in­sti­tute’s eq­ui­ty in­vest­ment in Xyphos Bio­sciences “isn’t triv­ial.” The pri­ma­ry pur­pose of the in­vest­ment — and the re­search al­liance that plugs Xyphos in­to their net­work of promi­nent in­ves­ti­ga­tors — is to ac­cel­er­ate the work and pre­vent it from get­ting stuck in the R&D mud.

And I’m just get­ting start­ed with the car metaphors, so buck­le up.

What at­tract­ed Park­er to the Bay Area im­munother­a­py play­er?

Gen­er­al­ly speak­ing, it’s their work on con­vert­ible CAR-Ts, re­volv­ing around NKG2D re­cep­tors on sev­er­al cell types, in­clud­ing T cells and NK killer cells that have fas­ci­nat­ed the field. 

Us­ing their pro­tein en­gi­neer­ing tech, the com­pa­ny craft­ed the nat­ur­al NKG2D re­cep­tor to be in­ac­tive un­til it’s turned on by their bis­pe­cif­ic an­ti­body. One end of the bis­pe­cif­ic binds to the re­cep­tors on the con­vert­ible CAR-T, with the oth­er end de­signed to bind to the tar­get­ed ma­lig­nant cell. Their col­li­sion is in­tend­ed to crush the can­cer cell.

There are sev­er­al ad­van­tages to the ap­proach, Blue­stone tells me. The safe­ty as­pect is en­hanced by the “reg­u­lat­ed sys­tem” Xyphos is us­ing. “You’re con­trol­ling to T cells: You can stop en­gag­ing the tar­get” — and that off switch can be hit in the event of a sud­den cy­tokine storm that can en­gulf a pa­tient, a rou­tine threat for the pro­to­type CAR-Ts on the mar­ket.

These bis­pecifics can al­so tar­get a cell se­quen­tial­ly, shift­ing tar­gets when a pa­tient starts to de­vel­op re­sis­tance, com­mon­ly lead­ing to a re­lapse. And while the work is still pre­clin­i­cal, Park­er’s in­vest­ment is in­tend­ed to push the team to­ward the clin­ic.

If it pans out, says Blue­stone, they’ll have a best-in-class ther­a­py able to go af­ter a va­ri­ety of sol­id tu­mors.

Park­er has done a num­ber of re­search al­liances with bio­phar­mas like Tes­sa, but steered on­ly a few eq­ui­ty in­vest­ments like this. They’ve backed the on­col­o­gy imag­ing out­fit Imag­inAb and Tmu­ni­ty, the start­up from Penn’s Carl June and Oz Azam, and now Xyphos. There are al­so a few in­vest­ments they’ve made which they’re still play­ing close to the vest.

They’re in for the long haul, with some near-term des­ti­na­tions in mind.

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Amarin’s shares $AMRN were blitzed Monday evening, losing billions in value as reports spread that the company had lost its high-profile effort to keep its Vascepa patents protected from generic drugmakers.

Amarin had been fighting to keep key patents under lock and key — and away from generic rivals — for another 10 years, but District Court Judge Miranda Du in Las Vegas ruled against the biotech. She ruled that:
(A)ll the Asserted Claims are invalid as obvious under 35 U.S.C.§ 103. Thus, the Court finds in favor of Defendants on Plaintiff’s remaining infringementclaim, and in their favor on their counterclaims asserting the invalidity of the AssertedClaims under 35 U.S.C. § 103.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Have a new drug that promis­es to fight Covid-19? The FDA promis­es fast ac­tion but some de­vel­op­ers aren't hap­py

After providing an emergency approval to use malaria drugs against coronavirus with little actual evidence of their efficacy or safety in that setting, the FDA has already proven that it has set aside the gold standard when it comes to the pandemic. And now regulators have spelled out a new approach to speeding development that promises immediate responses in no uncertain terms — promising a program offering the ultimate high-speed pathway to Covid-19 drug approvals.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

Back in the BP era — Before Pandemic — the FDA ripped Novartis for its decision to keep the agency in the dark about manipulated data used in its application for Zolgensma while its marketing application for the gene therapy was under review.

Civil and criminal sanctions were being discussed, the agency noted in a rare broadside at one of the world’s largest pharma companies. Notable lawmakers cheered the angry regulators on, urging the FDA to make an example of Novartis, which fielded Zolgensma at $2.1 million — the current record for a one-off therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic lab

You can add Amgen and GSK to the list of deep-pocket drug R&D players who are tailoring their pipeline work to fit a new age of coronavirus.

Following in the footsteps of a lineup of big players like Eli Lilly — which has suspended patient recruitment for drug studies — Amgen and GSK have opted to take a more tailored approach. Amgen is intent on circling the wagons around key studies that are already fully enrolled, and GSK has the red light on new studies while the pandemic plays out.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

The race to de­vel­op Covid-19 drugs and vac­cines is on — here’s what’s hap­pen­ing in the UK

Weeks away from the results of ongoing US and China trials testing its experimental antiviral remdesivir, Gilead is going to trial the failed Ebola drug in a small group of coronavirus patients in England and Scotland. The United Kingdom is also home to a range of other therapeutic efforts, as the pandemic rages on across the globe.

On Tuesday, Southampton, UK-based startup Synairgen kicked off a mid-stage placebo-controlled study testing its experimental drug, SNG001 — an inhaled formulation of interferon-beta-1a — that has previously shown to be safe and effective in improving lung function in asthma patients with a respiratory viral infection in a pair of Phase II trials.

‘There was a grow­ing weari­ness’: Rush­ing against a pan­dem­ic clock, As­pen Neu­ro­sciences se­cures $70M Se­ries A

Just before Christmastime, Howard Federoff got a tip from Washington: There was a new virus in China. And this one could be bad.

News report of the virus had not yet appeared. Federoff, a neuroscientist, was briefed because years before, he was vetted as part of a group — he didn’t give a name for the group — to consult for the US government on emerging scientific issues. His day job, though, was CEO of Aspen Neurosciences, a Parkinson’s cell therapy startup that days before had come out of stealth mode and gave word to investors they were hoping to raise $70 million. That, Federoff realized, would be difficult if a pandemic shut down the global economy.

FDA puts pe­di­atric aGVHD drug on pri­or­i­ty re­view lane — will they go vir­tu­al with the ad­comm?

Despite worries about regulatory delays due to new work arrangements under Covid-19, the FDA appears intent to go full speed ahead with its everyday work, not only granting priority review to a stem cell therapy for acute graft versus host disease but also plotting an advisory committee meeting for it.

With a PDUFA date of September 30, the journey of the drug — remestemcel-L, or Ryoncil — could shed light on the agency’s capacity to facilitate drug development unrelated to Covid-19.

Mene Pangalos via YouTube

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

If the FDA can still hold up its end of the bargain, AstraZeneca is already on a short path to scooping up a cutting-edge win with a likely approval for their SGLT2 drug Farxiga in cutting the risk of heart failure. Now the pharma giant says it can point to solid evidence that the drug — initially restricted to diabetes — also works for chronic kidney disease, potentially adding a blockbuster indication for the franchise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Trump push­es his new fa­vorite, untest­ed drug; CRISPR out­lines crip­pling im­pact of Covid-19

President Trump has a new favorite Covid-19 drug.

After a conversation with Japanese Prime Minister Shinzo Abe, Politico reports, the president is pressuring the FDA to issue emergency use authorization for favipiravir, a flu drug that showed glimpses of success in China but remains unproven and carries a list of worrying side effects. The push comes after a week-plus in which the White House touted a potentially effective but unproven malaria medication despite the concerns of scientific advisors such as NIAID director Anthony Fauci. And Trump ally Rudy Giuliani has been talking up unproven cell therapy efforts on Twitter.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.